Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors
Authors:
Open Access
- 29 September 2022
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 127 (11) , 2034-2042
Abstract
Background: Immune checkpoint inhibitors (ICIs) have revolutionised treatment of advanced non-small cell lung cancer (aNSCLC), but a proportion of patients had no clinical benefit and even experienced detrimental effects. This study aims to characterise patients experiencing hyperprogression (HPD) and early death (ED) by longitudinal liquid biopsy. Methods: aNSCLC receiving ICIs were prospectively enrolled. Plasma was collected at baseline (T1) and after 3/4 weeks of treatment, according to the treatment schedule (T2). Cell-free DNA (cfDNA) was quantified and analysed by NGS. cfDNA quantification and variant allele fraction (VAF) of tumour-associated genetic alterations were evaluated for their potential impact on outcome. The genetic alteration with the highest VAF (maxVAF) at baseline was considered as a reference. Results: From March 2017 to August 2019, 171 patients were enrolled. Five cases matched criteria for HPD and 31 ED were recorded; one overlapped. Quantification of cfDNA at T2 and its absolute and relative variation (T2–T1) were significantly associated with the risk of ED (P = 0.012, P = 0.005, P = 0.009). MaxVAF relative change (T2–T1/T1) was significantly associated with the risk of HPD (P = 0.02). After identifying optimal cut-off values, a two-step risk assessment model was proposed. Discussion: Liquid biopsy performed early during treatment has the potential to identify patients at high risk of ED and HPD.Keywords
Funding Information
- 5x1000 IOV intramural grant
This publication has 31 references indexed in Scilit:
- Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 BlockadeClinical Cancer Research, 2019
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent ChemotherapyJAMA Oncology, 2018
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2018
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth RateClinical Cancer Research, 2017
- Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept studyAnnals of Oncology, 2017
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1Clinical Cancer Research, 2017
- OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057Journal of Thoracic Oncology, 2017
- Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical TrialsClinical Cancer Research, 2014
- Tumour growth rates and RECIST criteria in early drug developmentEuropean Journal of Cancer, 2011